Ototoxicity Clinical Trial
Official title:
Prevention of Cisplatin Ototoxicity With the Antioxidant Alpha-Lipoic Acid
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin.
PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid
in preventing hearing loss in cancer patients undergoing treatment with cisplatin.
OBJECTIVES:
Primary
Determine the ability of alpha-lipoic acid supplementation to prevent or reduce the
incidence and severity of hearing loss in cancer patients undergoing treatment with
cisplatin.
Secondary
Determine if this drug improves the oxidative state, as measured by a malondialdehyde
measurement of oxidative stress, thereby protecting the patient against ototoxic-induced
hearing loss.
OUTLINE: This is a placebo-controlled, double-blind, randomized, multicenter study. Patients
are stratified by cancer stage and institution. Patients are randomized to 1 of 2 treatment
arms.
Arm I: Patients receive oral alpha-lipoic acid supplement once a day beginning 1 week before
the start of cisplatin treatment and continuing for up to 1 month after the completion of
cisplatin. During cisplatin treatment, patients discontinue supplement 1 day prior to the
cisplatin treatment and resume daily supplements 2 days post treatment.
Arm II: Patients receive oral placebo supplement once a day beginning 1 week before the
start of cisplatin and continuing for up to 1 month after the completion of cisplatin.
During cisplatin treatment, patients discontinue supplement 1 day prior to the cisplatin
treatment and resume daily supplements 2 days post treatment.
Hearing and ototoxicity are assessed at baseline, on each day of chemotherapy, and at 1 and
3 months post chemotherapy.
Blood samples are collected periodically to measure malondialdehyde and alpha-lipoic acid
levels.
After completion of treatment with cisplatin, patients are followed for 3 months.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01624324 -
Aminoglycoside Plasma Level Measurement in Neonates With Infection
|
N/A | |
Completed |
NCT00458887 -
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin
|
N/A | |
Recruiting |
NCT03480971 -
Treatment of Radiation and Cisplatin Induced Toxicities With Tempol
|
Phase 2 | |
Completed |
NCT00716976 -
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
|
Phase 3 | |
Completed |
NCT01139281 -
The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
|
Phase 2 | |
Enrolling by invitation |
NCT02819856 -
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
|
Phase 2 | |
Terminated |
NCT04226456 -
Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity
|
Phase 4 | |
Recruiting |
NCT05641441 -
Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma
|
||
Not yet recruiting |
NCT01285674 -
Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin.
|
N/A | |
Completed |
NCT01263262 -
A Comparison of Infection Rates Between Two Surgical Sites
|
N/A | |
Not yet recruiting |
NCT01451853 -
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
|
Phase 2 | |
Completed |
NCT04262336 -
Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
|
Phase 1 | |
Not yet recruiting |
NCT00578760 -
Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?
|
N/A | |
Completed |
NCT00652132 -
Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer
|
Phase 3 | |
Withdrawn |
NCT02382068 -
Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin
|
N/A | |
Recruiting |
NCT01216800 -
Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors
|
Phase 3 | |
Completed |
NCT01848457 -
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
|
Phase 2 | |
Active, not recruiting |
NCT00683319 -
Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy
|
Phase 3 |